Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?

Anna Wåhlén,1 Arvo Haenni,2,3 Hans-Erik Johansson1–3 1Östervåla Primary Health Care Centre, Östervåla, 2Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, 3Skönvikt, Outpatient Clinic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wåhlén A, Haenni A, Johansson HE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Metformin medication vitamin B12 magnesium type 2 diabetes mellitus morbidly obese Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1a0090ea0b344da597c47b4500adbe6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a0090ea0b344da597c47b4500adbe6b
record_format	dspace
spelling	oai:doaj.org-article:1a0090ea0b344da597c47b4500adbe6b2021-12-02T00:26:31ZDo we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?1178-7007https://doaj.org/article/1a0090ea0b344da597c47b4500adbe6b2017-05-01T00:00:00Zhttps://www.dovepress.com/do-we-need-to-measure-vitamin-b12-and-magnesium-in-morbidly-obese-pati-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Anna Wåhlén,1 Arvo Haenni,2,3 Hans-Erik Johansson1–3 1Östervåla Primary Health Care Centre, Östervåla, 2Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, 3Skönvikt, Outpatient Clinic of Obesity Care, Säter, Sweden Objective: We aimed to investigate the prevalence of B12 deficiency in metformin-treated, morbidly obese, type 2 diabetes mellitus (T2DM) patients, compared to morbidly obese controls, as well as to evaluate the magnesium status. Design: Retrospective cross-sectional analysis of plasma vitamin B12, plasma magnesium, glucometabolic status and clinical measurements in all consecutive morbidly obese patients was conducted during 1 year. Setting: Outpatient Clinic of Obesity Care. Subjects: One hundred forty-seven patients were evaluated: 107 morbidly obese controls and 40 metformin-treated, morbidly obese patients with T2DM. Main outcome measures: Circulating plasma concentrations of vitamin B12 (cobalamin), magnesium, clinical measurements and metformin medication. Results: There were differences between the two groups regarding age, sagittal diameter, glucose parameters and magnesium concentrations. Longer diabetes duration was associated with lower magnesium. Metformin-treated T2DM patients had lower magnesium (0.76±0.07 mmol/L) than controls (0.82±0.07 mmol/L). A subgroup analysis of 26 non-metformin-treated T2DM patients showed a normal magnesium concentration compared to controls, that is, 0.81±0.06 mmol/L. We found no statistical difference in B12 concentrations between the two groups. Conclusion: To fully benefit from metformin medication, routine testing of B12 as well as magnesium in metformin-treated, morbidly obese patients should be performed, with consideration of substitution to avoid low levels. Keywords: metformin medication, vitamin B12, magnesium, type 2 diabetes mellitus, morbidly obeseWåhlén AHaenni AJohansson HEDove Medical PressarticleMetformin medicationvitamin B12magnesiumtype 2 diabetes mellitusmorbidly obeseSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 151-154 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Metformin medication vitamin B12 magnesium type 2 diabetes mellitus morbidly obese Specialties of internal medicine RC581-951
spellingShingle	Metformin medication vitamin B12 magnesium type 2 diabetes mellitus morbidly obese Specialties of internal medicine RC581-951 Wåhlén A Haenni A Johansson HE Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
description	Anna Wåhlén,1 Arvo Haenni,2,3 Hans-Erik Johansson1–3 1Östervåla Primary Health Care Centre, Östervåla, 2Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, 3Skönvikt, Outpatient Clinic of Obesity Care, Säter, Sweden Objective: We aimed to investigate the prevalence of B12 deficiency in metformin-treated, morbidly obese, type 2 diabetes mellitus (T2DM) patients, compared to morbidly obese controls, as well as to evaluate the magnesium status. Design: Retrospective cross-sectional analysis of plasma vitamin B12, plasma magnesium, glucometabolic status and clinical measurements in all consecutive morbidly obese patients was conducted during 1 year. Setting: Outpatient Clinic of Obesity Care. Subjects: One hundred forty-seven patients were evaluated: 107 morbidly obese controls and 40 metformin-treated, morbidly obese patients with T2DM. Main outcome measures: Circulating plasma concentrations of vitamin B12 (cobalamin), magnesium, clinical measurements and metformin medication. Results: There were differences between the two groups regarding age, sagittal diameter, glucose parameters and magnesium concentrations. Longer diabetes duration was associated with lower magnesium. Metformin-treated T2DM patients had lower magnesium (0.76±0.07 mmol/L) than controls (0.82±0.07 mmol/L). A subgroup analysis of 26 non-metformin-treated T2DM patients showed a normal magnesium concentration compared to controls, that is, 0.81±0.06 mmol/L. We found no statistical difference in B12 concentrations between the two groups. Conclusion: To fully benefit from metformin medication, routine testing of B12 as well as magnesium in metformin-treated, morbidly obese patients should be performed, with consideration of substitution to avoid low levels. Keywords: metformin medication, vitamin B12, magnesium, type 2 diabetes mellitus, morbidly obese
format	article
author	Wåhlén A Haenni A Johansson HE
author_facet	Wåhlén A Haenni A Johansson HE
author_sort	Wåhlén A
title	Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
title_short	Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
title_full	Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
title_fullStr	Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
title_full_unstemmed	Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
title_sort	do we need to measure vitamin b12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/1a0090ea0b344da597c47b4500adbe6b
work_keys_str_mv	AT wahlena doweneedtomeasurevitaminb12andmagnesiuminmorbidlyobesepatientswithtype2diabetesmellitus AT haennia doweneedtomeasurevitaminb12andmagnesiuminmorbidlyobesepatientswithtype2diabetesmellitus AT johanssonhe doweneedtomeasurevitaminb12andmagnesiuminmorbidlyobesepatientswithtype2diabetesmellitus
_version_	1718403725581615104

Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus?

Ejemplares similares